Medial prefrontal cortical synapsin II knock-down induces behavioral abnormalities in the rat: Examining synapsin II in the pathophysiology of schizophrenia

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 250-259

  Dyck, Bailey A ^a   Beyaert, Michael G R ^a   Ferro, Mark A ^a   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antipsychotic drugs; Antisense deoxyoligonucleotides; GABA; Glutamate; Schizophrenia; Synapsin II

Indexed keywords

4 AMINOBUTYRIC ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; OLANZAPINE; SYNAPSIN II; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2; VESICULAR INHIBITORY AMINO ACID TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; LOCOMOTION; MALE; MEDIAL PREFRONTAL CORTEX; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORY GATING; SOCIAL BEHAVIOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; INHIBITION (PSYCHOLOGY); LOCOMOTION; MALE; MAZE LEARNING; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SENSORY GATING; SOCIAL BEHAVIOR; STARTLE REACTION; SYNAPSINS; VESICULAR NEUROTRANSMITTER TRANSPORT PROTEINS;

EID: 79960332700     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.017     Document Type: Article

References (41)

1. Bogen I.L., Haug K.H., Roberg B., Fonnum F., Walaas S.I. The importance of synapsin I and II for neurotransmitter levels and vesicular storage in cholinergic, glutamatergic and GABAergic nerve terminals. Neurochem. Int. 2009, 55:13-21.
2. Brady A.M. Neonatal ventral hippocampal lesions disrupt set-shifting ability in adult rats. Behav Brain Res. 2009, 205:294-298.
3. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001, 156:234-258.
4. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 2000, 61:231-265.
5. Castillo M.A., Ghose S., Tamminga C.A., Ulery-Reynolds P.G. Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry. 2010, 67:208-216.
6. Chetrit J., Ballion B., Laquitaine S., Belujon P., Morin S., Taupignon A., Bioulac B., Gross C.E., Benazzouz A. Involvement of Basal Ganglia network in motor disabilities induced by typical antipsychotics. PLoS One. 2009, 4:e6208.
7. Chong V., Tsang E., Gabriele J., Thomas N., Castellano J., Dyck B.A., Skoblenick K., Ki K., Mishra R.K. Decreased expression of medial prefrontal cortex synapsin II in schizophrenic specimens from the Stanley Foundation Neuropathology Consortium. Society for Neuroscience, Washington, DC, Abstract Viewer/Itinerary Planner 2005, 35:19-675.
8. Chong V.Z., Skoblenick K., Morin F., Xu Y., Mishra R.K. Dopamine-D1 and -D2 receptors differentially regulate synapsin II expression in the rat brain. Neuroscience 2006, 138:587-599.
9. Chong V.Z., Young L.T., Mishra R.K. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J. Neurochem. 2002, 82:1533-1539.
10. Coleman W.L., Bill C.A., Simsek-Duran F., Lonart G., Samigullin D., Bykhovskaia M. Synapsin II and calcium regulate vesicle docking and the cross-talk between vesicle pools at the mouse motor terminals. J. Physiol. 2008, 586:4649-4673.
11. Coleman W.L., Bykhovskaia M. Cooperative regulation of neurotransmitter release by Rab3a and synapsin II. Mol. Cell. Neurosci. 2010, 44:190-200.
12. Corradi A., Zanardi A., Giacomini C., Onofri F., Valtorta F., Zoli M., Benfenati F. Synapsin-I- and synapsin-II-null mice display an increased age-dependent cognitive impairment. J Cell Sci. 2008, 121:3042-3051.
13. Critchlow H.M., Maycox P.R., Skepper J.N., Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol. Cell. Neurosci. 2006, 32:356-365.
14. Didriksen M., Skarsfeldt T., Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl). 2007, 193:225-233.
15. Dyck B.A., Skoblenick K.J., Castellano J.M., Ki K., Thomas N., Mishra R.K. Synapsin II knockout mice show sensorimotor gating and behavioural abnormalities similar to those in the phencyclidine-induced preclinical animal model of schizophrenia. Schizophr. Res. 2007, 97:292-293.
16. Dyck B.A., Skoblenick K.J., Castellano J.M., Ki K., Thomas N., Mishra R.K. Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse 2009, 63:662-672.
17. Fdez E., Hilfiker S. Vesicle pools and synapsins: new insights into old enigmas. Brain Cell Biol. 2006, 35:107-115.
18. Ferreira A., Rapoport M. The synapsins: beyond the regulation of neurotransmitter release. Cell Mol Life Sci. 2002, 59:589-595.
19. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull. 1990, 25:485-498.
20. Gitler D., Cheng Q., Greengard P., Augustine G.J. Synapsin IIa controls the reserve pool of glutamatergic synaptic vesicles. J. Neurosci. 2008, 28:10,835-10,843.
21. Gitler D., Xu Y., Kao H.T., Lin D., Lim S., Feng J., Greengard P., Augustine G.J. Molecular determinants of synapsin targeting to presynaptic terminals. J. Neurosci. 2004, 24:3711-3720.
22. Guest K.A., Dyck B.A., Shethwala S., Mishra R.K. Atypical antipsychotic drugs upregulate synapsin II in the prefrontal cortex of post-mortem samples obtained from patients with schizophrenia 2010, Schizophr Res.
23. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122(Pt 4):593-624.
24. Imai C., Sugai T., Iritani S., Niizato K., Nakamura R., Makifuchi T., Kakita A., Takahashi H., Nawa H. A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosci. Lett. 2001, 305:185-188.
25. Keefe R.S., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33:912-920.
26. Kontkanen O., Toronen P., Lakso M., Wong G., Castren E. Antipsychotic drug treatment induces differential gene expression in the rat cortex. J. Neurochem. 2002, 83:1043-1053.
27. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270:1628-1644.
28. Le Pen G., Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27:1-11.
29. Lebedeva I., Stein C.A. Antisense oligonucleotides: promise and reality. Annu. Rev. Pharmacol. Toxicol. 2001, 41:403-419.
30. MacDonald M.L., Eaton M.E., Dudman J.T., Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry. 2005, 57:1041-1051.
31. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr. Opin. Pharmacol. 2004, 4:53-57.
32. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
33. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
34. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
35. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 1999, 10:59-90.
36. Savelli J.E., Chugh A., Cheng C., Mishra R.K., Johnson R.L. Modulation of N-methyl-d-aspartate (NMDA) antagonist-induced darting behaviour by the peptidomimetic PAMTA. Brain Res. 1995, 682:41-49.
37. Sawada K., Young C.E., Barr A.M., Longworth K., Takahashi S., Arango V., Mann J.J., Dwork A.J., Falkai P., Phillips A.G., Honer W.G. Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. Mol Psychiatry. 2002, 7:484-492.
38. Schleimer S.B., Hinton T., Dixon G., Johnston G.A. GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex in schizophrenia. Neuropsychobiology 2004, 50:226-230.
39. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci. Lett. 1991, 121:77-80.
40. Skoblenick K.J., Argintaru N., Xu Y., Dyck B.A., Tan M., Mazurek M.F., Mishra R.K. AP-2 alpha transcription factor in the regulation of synapsin II gene expression by dopamine D1 and D2 receptors. J Molecular Neurosci. 2010, 41:267-277.
41. Sudhof T.C., Czernik A.J., Kao H.T., Takei K., Johnston P.A., Horiuchi A., Kanazir S.D., Wagner M.A., Perin M.S., De Camilli P. Synapsins: mosaics of shared and individual domains in a family of synaptic vesicle phosphoproteins. Science 1989, 245:1474-1480.